Literature DB >> 35525794

The interactive role of inflammatory mediators and metabolic reprogramming in pancreatic cancer.

Yuuki Ohara1, Paloma Valenzuela1, S Perwez Hussain2.   

Abstract

Pancreatic ductal adenocarcinoma (PDAC) is characterized by its highly reactive inflammatory desmoplastic stroma with evidence of an extensive tumor stromal interaction largely mediated by inflammatory factors. KRAS mutation and inflammatory signaling promote protumorigenic events, including metabolic reprogramming with several inter-regulatory crosstalks to fulfill the high demand of energy and regulate oxidative stress for tumor growth and progression. Notably, the more aggressive molecular subtype of PDAC enhances influx of glycolytic intermediates. This review focuses on the interactive role of inflammatory signaling and metabolic reprogramming with emerging evidence of crosstalk, which supports the development, progression, and therapeutic resistance of PDAC. Understanding the emerging crosstalk between inflammation and metabolic adaptations may identify potential targets and develop novel therapeutic approaches for PDAC. Published by Elsevier Inc.

Entities:  

Keywords:  autophagy; inflammatory mediators; metabolic reprogramming; molecular subtype; pancreatic ductal adenocarcinoma (PDAC)

Mesh:

Substances:

Year:  2022        PMID: 35525794      PMCID: PMC9233125          DOI: 10.1016/j.trecan.2022.03.004

Source DB:  PubMed          Journal:  Trends Cancer        ISSN: 2405-8025


  110 in total

1.  Activating Immune Recognition in Pancreatic Ductal Adenocarcinoma via Autophagy Inhibition, MEK Blockade, and CD40 Agonism.

Authors:  Honglin Jiang; Tristan Courau; Joseph Borison; Alexa J Ritchie; Aaron T Mayer; Matthew F Krummel; Eric A Collisson
Journal:  Gastroenterology       Date:  2021-10-08       Impact factor: 22.682

2.  Neurons Release Serine to Support mRNA Translation in Pancreatic Cancer.

Authors:  Robert S Banh; Douglas E Biancur; Keisuke Yamamoto; Albert S W Sohn; Beth Walters; Miljan Kuljanin; Ajami Gikandi; Huamin Wang; Joseph D Mancias; Robert J Schneider; Michael E Pacold; Alec C Kimmelman
Journal:  Cell       Date:  2020-11-02       Impact factor: 41.582

3.  Combination of ERK and autophagy inhibition as a treatment approach for pancreatic cancer.

Authors:  Kirsten L Bryant; Clint A Stalnecker; Daniel Zeitouni; Jennifer E Klomp; Sen Peng; Andrey P Tikunov; Venugopal Gunda; Mariaelena Pierobon; Andrew M Waters; Samuel D George; Garima Tomar; Björn Papke; G Aaron Hobbs; Liang Yan; Tikvah K Hayes; J Nathaniel Diehl; Gennifer D Goode; Nina V Chaika; Yingxue Wang; Guo-Fang Zhang; Agnieszka K Witkiewicz; Erik S Knudsen; Emanuel F Petricoin; Pankaj K Singh; Jeffrey M Macdonald; Nhan L Tran; Costas A Lyssiotis; Haoqiang Ying; Alec C Kimmelman; Adrienne D Cox; Channing J Der
Journal:  Nat Med       Date:  2019-03-04       Impact factor: 53.440

4.  Collagen-derived proline promotes pancreatic ductal adenocarcinoma cell survival under nutrient limited conditions.

Authors:  Orianne Olivares; Jared R Mayers; Victoire Gouirand; Margaret E Torrence; Tristan Gicquel; Laurence Borge; Sophie Lac; Julie Roques; Marie-Noëlle Lavaut; Patrice Berthezène; Marion Rubis; Veronique Secq; Stéphane Garcia; Vincent Moutardier; Dominique Lombardo; Juan Lucio Iovanna; Richard Tomasini; Fabienne Guillaumond; Matthew G Vander Heiden; Sophie Vasseur
Journal:  Nat Commun       Date:  2017-07-07       Impact factor: 14.919

5.  Hepatocytes direct the formation of a pro-metastatic niche in the liver.

Authors:  Jae W Lee; Meredith L Stone; Paige M Porrett; Stacy K Thomas; Chad A Komar; Joey H Li; Devora Delman; Kathleen Graham; Whitney L Gladney; Xia Hua; Taylor A Black; Austin L Chien; Krishna S Majmundar; Jeffrey C Thompson; Stephanie S Yee; Mark H O'Hara; Charu Aggarwal; Dong Xin; Abraham Shaked; Mingming Gao; Dexi Liu; Mitesh J Borad; Ramesh K Ramanathan; Erica L Carpenter; Ailing Ji; Maria C de Beer; Frederick C de Beer; Nancy R Webb; Gregory L Beatty
Journal:  Nature       Date:  2019-03-06       Impact factor: 49.962

Review 6.  Cytokines in clinical cancer immunotherapy.

Authors:  Pedro Berraondo; Miguel F Sanmamed; María C Ochoa; Iñaki Etxeberria; Maria A Aznar; José Luis Pérez-Gracia; María E Rodríguez-Ruiz; Mariano Ponz-Sarvise; Eduardo Castañón; Ignacio Melero
Journal:  Br J Cancer       Date:  2018-11-09       Impact factor: 7.640

7.  Oncogenic KRAS-Driven Metabolic Reprogramming in Pancreatic Cancer Cells Utilizes Cytokines from the Tumor Microenvironment.

Authors:  Prasenjit Dey; Jun Li; Jianhua Zhang; Surendra Chaurasiya; Anders Strom; Huamin Wang; Wen-Ting Liao; Frederick Cavallaro; Parker Denz; Vincent Bernard; Er-Yen Yen; Giannicola Genovese; Pat Gulhati; Jielin Liu; Deepavali Chakravarti; Pingna Deng; Tingxin Zhang; Federica Carbone; Qing Chang; Haoqiang Ying; Xiaoying Shang; Denise J Spring; Bidyut Ghosh; Nagireddy Putluri; Anirban Maitra; Y Alan Wang; Ronald A DePinho
Journal:  Cancer Discov       Date:  2020-02-11       Impact factor: 39.397

Review 8.  Metabolic networks in mutant KRAS-driven tumours: tissue specificities and the microenvironment.

Authors:  Samuel A Kerk; Thales Papagiannakopoulos; Yatrik M Shah; Costas A Lyssiotis
Journal:  Nat Rev Cancer       Date:  2021-07-09       Impact factor: 69.800

9.  Pancreatic stellate cells support tumour metabolism through autophagic alanine secretion.

Authors:  Cristovão M Sousa; Douglas E Biancur; Xiaoxu Wang; Christopher J Halbrook; Mara H Sherman; Li Zhang; Daniel Kremer; Rosa F Hwang; Agnes K Witkiewicz; Haoqiang Ying; John M Asara; Ronald M Evans; Lewis C Cantley; Costas A Lyssiotis; Alec C Kimmelman
Journal:  Nature       Date:  2016-08-10       Impact factor: 49.962

10.  CXCR2 Inhibition Profoundly Suppresses Metastases and Augments Immunotherapy in Pancreatic Ductal Adenocarcinoma.

Authors:  Colin W Steele; Saadia A Karim; Joshua D G Leach; Peter Bailey; Rosanna Upstill-Goddard; Loveena Rishi; Mona Foth; Sheila Bryson; Karen McDaid; Zena Wilson; Catherine Eberlein; Juliana B Candido; Mairi Clarke; Colin Nixon; John Connelly; Nigel Jamieson; C Ross Carter; Frances Balkwill; David K Chang; T R Jeffry Evans; Douglas Strathdee; Andrew V Biankin; Robert J B Nibbs; Simon T Barry; Owen J Sansom; Jennifer P Morton
Journal:  Cancer Cell       Date:  2016-06-02       Impact factor: 38.585

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.